Close this search box.

We are creating some awesome events for you. Kindly bear with us.

HKSTP Biotech Makes Great Strides

HKSTP Biotech Makes Great Strides
Image Credits: HKSTP, Press Release

A Hong Kong Science and Technology Parks Corporation (HKSTP) recently announced that one of its partner companies officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited.

The partner company is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics.

The company is one of a few select biopharmaceutical companies in the Greater China Region that has a full-fledged capability. It has built a platform with an industry chain allocation to standardise and systemically monitor its R&D, clinical trials and manufacturing process.

This comprehensive platform integrates all-industry functionalities, including target identification, drug candidate development, pre-clinical research, clinical trials, clinical production, quality control and quality assurance, regulatory approval and commercial-scale production up to the commercialisation stage.

The Executive Director, Chairman of the Board and Chief Executive Officer of the company stated at the listing ceremony, that the firm is profoundly honoured to be the first local Hong Kong-based biopharmaceutical company listed on the Main Board of SEHK.

The company officially entered the Hong Kong stock market and tapped into the international capital market, marking an important milestone in the development of the Company’s development history.

Looking ahead, the aim is to expeditiously promote the commercialisation of SM03, further expand the pipeline of drugs candidates, continue discovering and developing novel drugs for the treatment of immunological diseases by leveraging its R&D capabilities, expand production scale and strengthen global businesses, striving to contribute to global and Chinese biomedical innovation.

The CEO of HKSTP stated that HKSTP is proud of the firm’s new chapter to its public listing. The company represents a shining example for other biomedical companies in the ecosystem that substantial value and prosperity could be added to their businesses through continuous research and development.

The company’s team was congratulated for their successful listing and it is hoped that this new position will give birth to more novel products and technologies.

HKSTP strives to nurture biomedical start-ups by providing them with the best environment and support, as well as connecting them with market and investment opportunities.

The Park is working to see more of its homegrown biomedical companies achieve the success that the company has achieved.

As of 22 October 2019, the biopharmaceutical company has built up a product pipeline consisting of six drug candidates, including a portfolio of first-in-target and first-in-class drug candidates.

The most near-commercialisation candidate SM03 is clinically proven, first-in-target anti-CD22 mAb for the treatment of RA and potentially other immunological diseases. SM03 is currently in Phase III clinical trial for RA in China, and patient enrolment is aimed to be completed by the end of 2019.

Biomedical technology is one of HKSTP’s technology focus areas, with Hong Kong Science Park currently hosting more than 120 biotechnology companies who work in speciality areas such as medical devices, molecular diagnoses, stem cell therapy, regenerative medicine, Chinese herbal medicine and advanced therapeutics.

The Park offers a range of incubation and acceleration services, such as the Incu-Bio programme, a four-year all-around programme in support of the growth of biomedical start-ups, funding and investment, and a host of support services such as well-equipped shared laboratories and market development services.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.